Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Sees Future For Premature Baby Drug Despite PhII Disappointment

Executive Summary

Shire's product candidate for a rare eye disease in premature infants has failed in a Phase II study, but secondary endpoint data suggest SHP607 might still have a future.

Advertisement

Related Content

Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
Shire buys Premacure for infant eye treatment

Topics

Advertisement
UsernamePublicRestriction

Register

SC065566

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel